Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients

Journal of the American College of Cardiology

Volumn 28, Issue 1, 1996, Pages 7-11

  Braun, Shimon ^a   Boyko, Valentina ^b   Behar, Solomon ^b   Reicher Reiss, Henrietta ^b   Shotan, Avi ^b   Schlesinger, Zwi ^c   Rosenfeld, Tiberio ^d   Palant, Abraham ^e   Friedensohn, Aharon ^c   Laniado, Shlomo ^a   Goldbourt, Uri ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d HAEMEK MEDICAL CENTER   (Israel)

^e CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIURETIC AGENT; NIFEDIPINE; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; SMOKING;

EID: 2042455581     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00109-X     Document Type: Article

References (25)

1. 1. Braunwald E, Muller JE, Stone PH. Use of calcium blocking agents in the management of ischemic heart disease. Eur Heart J 1985;6 Suppl A:31-6.
2. 2. Rice KR, Gervino E, Jarisc WR, Stone PH. Effects of nifedipine on myocardial perfusion during exercise in chronic stable angina. Am J Cardiol 1990;65:1097-1101.
3. 3. Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol 1994;73:28A-33A.
4. 4. Cone PF, Vetrovec GW, Nesto R, et al. The Nifedipine-Total Ischemia Awareness Program: a national survey of painful and painless myocardial ischemia including results of anti-ischemic therapy. Am J Cardiol 1984;63: 534-9.
5. 5. Frishman WH, Rosenberg A, Katz B. Calcium antagonist in the management of systemic hypertension: the impact of sustained-release drug delivery systems. Coron Artery Dis 1994;5:4-13.
6. 6. Held PH, Yusuf S, Furberg CD. Calcium blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299:1187-92.
7. 7. Yusuf S, Held P, Furberg CD. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT=II) and other recent studies. Am J Cardiol 1991;67:1295-7.
8. 8. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. SPRINT-2 study. Arch Intern Med 1993;153:345-53.
9. 9. Lichtlen PR, Hugenhultz PG, Raffenbuell W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT group. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiathersclerotic Therapy (INTACT). Lancet 1990;335:1109-13.
10. 10. Waters D. Proischemic complications of ischemic cardiac pain by nifedipine. BMJ 1978;1:1181-2.
11. 11. Multicenter Diltiazen Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
12. 12. Calcium antagonist caution [editorial]. Lancet 1991;337:885-6.
13. 13. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprotol or both. Br Heart J 1986;56:400-13.
14. 14. Psaty BM, Heckhert SR, Koepsell TD, et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995;274:620-5.
15. 15. Furberg CD, Psaty MP, Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
16. 16. Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of secondary prevention of increased serum high-density lipoprotein cholesterol and reduced triglycerides in patients clinically manifesting atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993;71:909-15.
17. 17. Cox DR. Regression methods of life tables. J R Stat Soc 1972;B34:187-220.
18. 18. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened acute myocardial infarction: a randomized, double blind, placebo controlled comparison. Circulation 1984;69:740-7.
19. 19. Muller JE, Turi ZG, Pearle D, et al. Nifedipine and conventional therapy for unstable angina pectoris: a random double blind comparison. Circulation 1984;69:728-39.
20. 20. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-73.
21. 21. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123:888-9.
22. 22. Yusuf S. Calcium antagonist in coronary artery disease and hypertension: time for re-evaluation. Circulation 1995;92:1079-82.
23. 23. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92: 1074-8.
24. 24. Lenfant C. The calcium blocker scare: lesson for the future. Circulation 1995;91:2855-6.
25. 25. Jackson G. Calcium antagonist: when the content does not justify the headline. Br J Clin Pharmacol 1995;19:283-4.